Scientists and clinicians have long dreamed of delivering the right drug in the right dose to a cancer patient without all the trial and error we experience today. Genome-based advances have allowed for real progress by identifying biomarkers that can be used to subtype cancer and stratify patients, often highlighting classes of therapeutics that are…